NF-κB inhibitors induce lytic cytotoxicity in Epstein-Barr virus-positive nasopharyngeal carcinoma cells

Cell Biology International

Volumn 32, Issue 8, 2008, Pages 1006-1013

  Liu, Su Fang ^a   Wang, Hai ^a   Lin, Xu Chi ^a   Xiang, Hui ^b   Deng, Xi Yun ^a   Li, Wei ^a   Tang, Min ^a   Cao, Ya ^a  

^a Central South University   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Bay11 7082; Epstein Barr virus; Lytic replication; Nuclear factor kappaB; Z LLF CHO

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; BENZYLOXYCARBONYLLEUCYLLEUCYLPHENYLALANINAL; GANCICLOVIR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; 3-(4-METHYLPHENYLSULFONYL)-2-PROPENENITRILE; ANTIVIRUS AGENT; N BENZYLOXYCARBONYL LEUCYL LEUCYL PHENYLALANINAL; N-BENZYLOXYCARBONYL-LEUCYL-LEUCYL-PHENYLALANINAL; NITRILE; OLIGOPEPTIDE; SULFONE; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL DIVISION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; NONHUMAN; VIRUS REPLICATION; CELL NUCLEUS; CYTOPLASM; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NASOPHARYNX TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY; VIRUS ACTIVATION; VIRUS INFECTION;

HUMAN HERPESVIRUS 4;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; EPSTEIN-BARR VIRUS INFECTIONS; GANCICLOVIR; HERPESVIRUS 4, HUMAN; HUMANS; NASOPHARYNGEAL NEOPLASMS; NF-KAPPA B; NITRILES; OLIGOPEPTIDES; SULFONES; TRANSCRIPTION FACTOR RELA; VIRUS ACTIVATION;

EID: 47349133539     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2008.03.022     Document Type: Article

References (31)

1. Anan A., Baskin-Bey E.S., Bronk S.F., Werneburg N.W., Shah V.H., and Gores G.J. Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology 43 2 (2006) 335-344
2. Brown H.J., Song M.J., Deng H., Wu T.T., Cheng G., and Sun R. NF-kappaB inhibits gamma herpes virus lytic replication. J Virol 77 15 (2003) 8532-8540
3. Chen Y.L., Law P.Y., and Loh H.H. Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chem Anticancer Agents 5 6 (2005) 575-589
4. Cheng W.M., Chan K.H., Chen H.L., Luo R.X., Ng S.P., Luk W., et al. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. Int J Cancer 97 4 (2002) 489-492
5. Feng W.H., Israel B., Raab-Traub N., Busson P., and Kenney S.C. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 62 6 (2002) 1920-1926
6. Feng W.H., and Kenney S.C. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 66 17 (2006) 8762-8769
7. Flemington E.K. Herpes virus lytic replication and the cell cycle: arresting new developments. J Virol 75 10 (2001) 4475-4481
8. Gardella T., Medveczky P., Sairenji T., and Mulder C. Detection of circular and linear herpes virus DNA molecules in mammalian cells by gel electrophoresis. J Virol 50 1 (1984) 248-254
9. Gutierrez M.I., Judde J.G., Magrath I.T., and Bhatia K.G. Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia. Cancer Res 56 5 (1996) 969-972
10. Gutsch D.E., Holley-Guthrie E.A., Zhang Q., Stein B., Blanar M.A., Baldwin A.S., et al. The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B. Mol Cell Biol 14 3 (1994) 1939-1948
11. Harabuchi Y., Yamanaka N., Kataura A., Imai S., Kinoshita T., Mizuno F., et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335 8682 (1990) 128-130
12. Huang J., Chen H., Hutt-Fletcher L., Ambinder R.F., and Hayward S.D. Lytic viral replication as a contributor to the detection of Epstein-Barr virus in breast cancer. J Virol 77 24 (2003) 13267-13274
13. Huen D.S., Henderson S.A., Croom-Carter D., and Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10 3 (1995) 549-560
14. Israel B.F., and Kenney S.C. Virally targeted therapies for EBV-associated malignancies. Oncogene 22 33 (2003) 5122-5130
15. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2 4 (2002) 301-310
16. Landais E., Saulquin X., Scotet E., Trautmann L., Peyrat M.A., Yates J.L., et al. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood 103 4 (2004) 1408-1416
17. Lee E.S., Locker J., Nalesnik M., Reyes J., Jaffe R., Alashari M., et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med 332 1 (1995) 19-25
18. Lin S.Y., Makino K., Xia W., Matin A., Wen Y., Kwong K.Y., et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3 9 (2001) 802-808
19. Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol Pathol 53 5 (2000) 248-254
20. Pathmanathan R., Prasad U., Sadler R., Flynn K., and Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 333 11 (1995) 693-698
21. Prince S., Keating S., Fielding C., Brennan P., Floettmann E., and Rowe M. Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. J Virol 77 8 (2003) 5000-5007
22. Rickinson A., and Kieff E. Epstein-Barr virus. In: Field B., Knipe D., and Howley P. (Eds). Fields virology. 3rd ed. (1996), Lippincott-Raven Publishers, Philadelphia 2397-2415
23. Schauer S.L., Bellas R.E., and Sonenshein G.E. Dominant signals leading to inhibitor kappaB protein degradation mediate CD40 ligand rescue of WEHI 231 immature B cells from receptor-mediated apoptosis. J Immunol 160 9 (1998) 4398-4405
24. Shibata D., and Weiss L.M. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 140 4 (1992) 769-774
25. Silvestri G.A., and Rivera M.P. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 128 6 (2005) 3975-3984
26. Sugawara Y., Makuuchi M., and Takada K. Detection of Epstein-Barr virus DNA in hepatocellular carcinoma tissues from hepatitis C-positive patients. Scand J Gastroenterol 35 9 (2000) 981-984
27. Vermeulen L., De Wilde G., Notebaert S., Vanden Berghe W., and Haegeman G. Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol 64 5-6 (2002) 963-970
28. Wang H., Zhao Y., Zeng L., Tang M., El-Deeb A., Li J.J., et al. BZLF1 controlled by family repeat domain induces lytic cytotoxicity in Epstein-Barr virus-positive tumor cells. Anticancer Res 24 1 (2004) 67-74
29. Yin L., Liao W., Deng X., Tang M., Gu H., Li X., et al. LMP1 activates NF-kappa B via degradation of I kappa B alpha in nasopharyngeal carcinoma cells. Chin Med J (Engl) 114 7 (2001) 718-722
30. Young L.S., and Rickinson A.B. Epstein-Barr virus: 40 years on. Nat Rev Cancer 4 10 (2004) 757-768
31. Young L.S., and Rowe M. Epstein-Barr virus, lymphomas and Hodgkin's disease. Semin Cancer Biol 3 5 (1992) 273-284